Eiger BioPharmaceuticals, Inc.

EIGRQ · OTC
Analyze with AI
12/31/2023
9/30/2023
6/30/2023
3/31/2023
Operating Activities
Net Income-$13,454-$18,030-$20,695-$22,784
Dep. & Amort.$180$198$183$189
Deferred Tax$0$0$0$0
Stock-Based Comp.$683$1,038$745$2,542
Change in WC-$1,679$2,122-$2,224-$3,952
Other Non-Cash$5,011$282$2,373$4,357
Operating Cash Flow-$13,954-$14,554-$22,035-$24,005
Investing Activities
PP&E Inv.-$1$0-$17-$216
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0-$19,388
Inv. Sales/Matur.$12,000$19,000$29,863$32,987
Other Inv. Act.$12,000$19,000$29,863$13,599
Investing Cash Flow$11,999$19,000$29,846$13,383
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$7$15-$22$41
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$7$15-$22$41
Financing Cash Flow$7$15-$22$41
Forex Effect-$113$57$13-$36
Net Chg. in Cash-$2,061$4,518$7,802-$10,617
Supplemental Information
Beg. Cash$27,501$22,983$15,181$25,798
End Cash$25,440$27,501$22,983$15,181
Free Cash Flow-$13,955-$14,554-$22,052-$24,221
Eiger BioPharmaceuticals, Inc. (EIGRQ) Financial Statements & Key Stats | AlphaPilot